Hepatitis B e antigen-negative chronic hepatitis B

Hepatology

Volumn 34, Issue 4 I, 2001, Pages 617-624

  Hadziyannis, Stephanos J ^a,b   Vassilopoulos, Dimitrios ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Department of Medicine of Henry Dynan Hospital ^*  (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS B ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE;

CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; INCIDENCE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROCONVERSION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0034802538     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.27834     Document Type: Review

References (114)

1. Type B hepatitis: Virology, serology and clinical course
2. Hepatitis B virus infection: The impact of molecular biology
3. Chronic hepatitis B
4. Anti-HBe positive chronic active hepatitis
5. Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver
6. Detection of hepatitis B virus DNA in liver and serum: A direct appraisal of the chronic carrier state
7. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus
8. A HBV variant is responsible for anti-HBe positive hepatitis B
9. Point mutations in the pre-core regions of HBV in anti-HBe positive patients with chronic hepatitis and persistent HBV replication
10. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
11. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B
12. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment
13. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections
14. Clinical relevance of hepatitis B viral mutations
15. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
16. Long-term therapy of chronic hepatitis B with lamivudine
17. Response of pre-core mutant chronic hepatitis B infection to lamivudine
18. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
19. Management of hepatitis B: Summary recommendations of a workshop
20. Hepatitis B: An important public health issue
21. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
22. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany
23. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong
24. Prevalence of hepatitis B infection in the general population: A rural community based study
25. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare, Zimbabwe, 1996 to 1997
26. Pre-core mutant infections in the Canadian Inuit
27. Natural history of chronic hepatitis B virus infection: An immunopathological study
28. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B
29. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: Possible contribution of a single nucleotide in the precore region
30. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - Large-scale analysis using a new genotyping method
31. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients
32. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: Correlation with viral persistence and disease severity
33. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels
34. High circulation of hepatitis B virus (HBV) precore mutants in Tunisia, North Africa
35. Polymorphism of precore region of hepatitis B virus DNA among patients with chronic HBV infection in Turkey
36. Epidemiology of precore mutants of hepatitis B in the United Kingdom
37. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland
38. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion
39. Prevalence of core promoter and precore mutants of hepatitis B virus in Thailand by RFLP and sequencing
40. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients
41. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection
42. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen
43. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis
44. Precore stop codon mutant in chronic hepatitis B virus infection in children: Its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen
45. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence
46. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?
47. Infection of the fetus with hepatitis B e antigen via the placenta
48. The hepatitis B virus core and e antigens elicit different Th cell subsets: Antigen structure can affect Th cell phenotype
49. Hepatitis B virus infection
50. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region
51. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections
52. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection
53. Naturally occurring hepatitis B virus core gene mutations
54. Long-term mutation rates in the hepatitis B virus genome
55. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers
56. Hepatitis B virus e antigen specific epitopes and limitations of commercial anti-HBe immunoassays
57. Serology of acute exacerbation in chronic hepatitis B virus infection
58. Hepatocytes of double-transgenic mice expressing high levels of hepatitis B virus e antigen and interferon-gamma are not injured by HBeAg specific autoantibodies
59. Differential antigen-processing pathways of the hepatitis B virus e and core proteins
60. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice
61. Nondeletional T-cell receptor transgenic mice: Model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection
62. Do T cells "see" the hepatitis B core and e antigens differently?
63. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes
64. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection
65. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal
66. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen
67. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation
68. Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression
69. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection
70. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: Comparison with mutations in precore and core regions in relation to clinical status
71. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus
72. Hepatitis B virus immunopathogenesis
73. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease
74. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury
75. HBV reactivation in anti-HBe positive HBsAg carriers
76. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B
77. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology
78. Viral clearance without destruction of infected cells during acute HBV infection
79. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis
80. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
81. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
82. Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B
83. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe
84. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
85. Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen
86. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France
87. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity
88. Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection
89. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc
90. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection
91. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values
92. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B?
93. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen
94. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis
95. The window period between hepatitis B e antigen and antibody in chronic type hepatitis
96. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection
97. Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection
98. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis
99. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis
100. Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B
101. IgM anti-HBc in anti-HBe positive chronic type B hepatitis with acute exacerbations
102. Spontaneous reactivation in chronic hepatitis B: Patterns and natural history
103. Frequent integration of precore/core mutants of hepatitis B virus in human hepatocellular carcinoma tissues
104. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
105. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: A randomized study
106. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon
107. Interferon-alpha treatment and re-treatment of hepatitis B e antigen negative chronic hepatitis B
108. Randomised trial in hepatitis B e antigen negative patients with replicating virus with ganciclovir vs lamivudine in combination with IFN-a. Evaluation of long-term efficacy
109. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B
110. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
111. HBV reactivation and biochemical breakthroughs after initially effective lamivudine therapy in patients with precore mutant HBV related liver disease
112. In vivo suppression of precore mRNA synthesis from the hepatitis B virus core promoter in patients with chronic hepatitis B
113. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
114. Antiviral chemotherapy for the treatment of hepatitis B virus infections